Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
2024

Safety and Efficacy of Pegylated Interferon Therapy in Liver Cirrhosis Patients

Sample size: 54 publication Evidence: moderate

Author Information

Author(s): Wang Zehong, Wang Xuanxuan, Zhou Li, Shi Shaoyuan, Hua Yongli, Feng Yinong

Primary Institution: Department of Hepatology, The Third People’s Hospital of Taiyuan, Taiyuan, Shanxi Province, China

Hypothesis

Can pegylated interferon-α-2b therapy improve outcomes in patients with hepatitis B virus-related compensated liver cirrhosis?

Conclusion

A finite course of PEG-IFN-α-2b therapy was well-tolerated and reduced HBsAg levels without accelerating disease progression in patients with HBV-related compensated cirrhosis.

Supporting Evidence

  • 42 patients achieved undetectable serum HBV DNA at 48 weeks post-therapy.
  • HBsAg level was significantly reduced at 48 weeks post-therapy.
  • Three patients achieved HBsAg loss, and two obtained HBsAg seroconversion.
  • No patients suffered from virological breakthrough or progressed to end-stage liver diseases during the observational period.

Takeaway

This study tested a medicine called PEG-IFN-α-2b on patients with liver problems from hepatitis B, and it helped lower a harmful substance in their blood without making their condition worse.

Methodology

This was a single-center, prospective, observational study where patients received PEG-IFN-α-2b therapy for 48 weeks, and various clinical and laboratory assessments were conducted.

Limitations

The study was limited by its small sample size and single-center design, and it only observed 48 weeks of treatment.

Participant Demographics

{"male_percentage":61.11,"mean_age":43.02,"treatment_naive_percentage":55.56,"nucleoside_analog_experienced_percentage":44.44}

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fmed.2024.1489671

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication